Immunotherapy Withdrawals Put Spotlight on Accelerated Approval

Elie Dolgin • June 1, 2021

The FDA's Accelerated Approval program is under scrutiny after four drug companies announced plans in recent months to withdraw indications for checkpoint inhibitors that, despite showing early promise, failed to demonstrate a survival benefit in confirmatory trials. The agency's Oncologic Drugs Advisory Committee will meet in late April to discuss whether six more indications for some of these same immunotherapies should be nullified as well.

Continue reading at Cancer Discovery.

Clock face, DNA strand and assortment of animals: dolphins, deer, bears, whale, baboon
By Elie Dolgin September 22, 2025
Molecular signatures of aging are changing how conservationists assess population health, resilience and risk.
Yellow rings of DNA amidst white chromosomes
By Elie Dolgin September 11, 2025
Paul Mischel is championing the importance of odd rings of DNA in tumors — and their promise as targets for cancer therapy.